Public Profile

KALA BIO, Inc.

KALA BIO, Inc., a pioneering biotechnology firm headquartered in the United States, focuses on developing innovative therapies for patients with serious diseases. Founded in 2018, the company has quickly established itself in the biopharmaceutical industry, particularly in the realm of gene therapy and precision medicine. KALA BIO's core offerings include advanced gene delivery systems designed to enhance therapeutic efficacy and safety. Their unique approach leverages proprietary technology to address unmet medical needs, setting them apart in a competitive market. With a commitment to scientific excellence, KALA BIO has achieved significant milestones, positioning itself as a leader in the development of transformative treatments. The company continues to expand its operational footprint, aiming to make a lasting impact on patient care globally.

DitchCarbon Score

How does KALA BIO, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

KALA BIO, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.

84%

KALA BIO, Inc.'s reported carbon emissions

KALA BIO, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives related to climate commitments. Without specific emissions figures or defined goals, it is challenging to assess their environmental impact or progress in reducing carbon emissions. The absence of data suggests that KALA BIO may still be in the early stages of developing a comprehensive climate strategy. As the industry increasingly prioritises sustainability, it will be essential for KALA BIO to establish clear commitments and measurable targets to align with global climate action efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. KALA BIO, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. KALA BIO, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

KALA BIO, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Oyster Point Pharma, Inc.

US
Health and social work services (85)
Updated 6 days ago
DitchCarbon Score

Sun Pharmaceutical Industries Inc.

US
Chemicals nec
Updated 6 days ago
DitchCarbon Score

Sun Pharmaceutical Industries

IN
Medical, precision and optical instruments, watches and clocks (33)
Updated about 21 hours ago

Abbvie

US
Chemicals nec
Updated 1 day ago

Aerie Pharmaceuticals, Inc.

US
Chemicals nec
Updated 6 days ago
DitchCarbon Score

Novartis Pharmaceuticals Corporation

US
Chemicals nec
Updated 6 days ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers